Follow the people · Insider
Keith Anthony Jones
Keith Anthony Jones files insider transactions with the SEC as a director of Humacyte (HUMA). We hold 2 disclosed purchases and sales filed since 17 June 2024, 2 of them in the last 90 days.
- Files forHUMA
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure21 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 June 2024 — 20 August 2026Director · Humacyte (HUMA)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
5 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 10,000 shares of HumacyteSEC Form 421 August 2026Common Stock · traded 20 August 2026 · filed 21 August 2026
- ▲ bought on the open market 30,000 shares of HumacyteSEC Form 419 August 2026Common Stock · traded 17 August 2026 · filed 19 August 2026
- was granted 80,000 shares of Humacyte (a derivative holding)SEC Form 412 June 2026Stock Options (right to buy) · traded 11 June 2026 · filed 12 June 2026
- was granted 80,000 shares of Humacyte (a derivative holding)SEC Form 416 June 2025Stock Options (right to buy) · traded 12 June 2025 · filed 16 June 2025
- was granted 75,000 shares of Humacyte (a derivative holding)SEC Form 417 June 2024Stock Options (right to buy) · traded 13 June 2024 · filed 17 June 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.